睿知中国医院研究地图
候选清单

即将招募乳腺癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由湖南省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07163481,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 9

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(9 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically documented breast cancer that:

    入选标准第 8 条

  3. New York Heart Association (NYHA) class III or greater congestive heart failure or left ventricular ejection fraction of < 40%.

    排除标准第 20 条

  4. Patients who received adjuvant endocrine therapy with or without CDK4/6i with curative intent for early breast cancer are eligible, as long as they relapse after the first 24 months of adjuvant endocrine therapy.

    入选标准第 13 条

    No prior chemotherapy for advanced or metastatic breast cancer. Patients who have received chemotherapy in the neo-adjuvant or adjuvant setting are eligible, as long as they have had a disease-free interval (defined as completion of systemic chemotherapy to the diagnosis of advanced or metastatic disease) of >12 months.

    入选标准第 14 条

    Recovered from all prior treatment-related toxicities to Grade 1 or less by NCI-CTCAE v 5.0 (except alopecia or peripheral neuropathy, which should be Grade 2 or less).

    入选标准第 19 条

    Women of childbearing potential or fertile men unwilling to use highly effective contraception during the study and up to 6 months after treatment discontinuation in women of childbearing potential and 3 months in males post last IP administration.

    排除标准第 2 条

    Have had a prior anticancer biologic agent within 4 weeks prior to enrollment or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to enrollment and have not recovered (i.e., ≥ Grade 2 is considered not recovered) from AEs at the time of study entry.

    排除标准第 5 条

    Have previously received treatment in advanced or metastatic setting with systemic therapy before or after the first line CDK4/6i combined with ET, including but not limited to:

    排除标准第 10 条

    Have an active second malignancy. Note: patients with a history of malignancy that have been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or patients with surgically cured tumors with low risk of recurrence (e.g., nonmelanoma skin cancer, histologically confirmed complete excision of carcinoma in situ, or similar) are allowed to enroll.

    排除标准第 16 条

  5. ECOG performance status of 0 or 1.

    入选标准第 2 条

  6. Creatinine clearance ≥ 30 mL/min as assessed by the Cockcroft-Gault equation

    入选标准第 18 条

  7. Measurable disease by CT or MRI in accordance with RECIST v 1.1, the bone-only disease was not measurable and was not permitted.

    入选标准第 15 条

  8. Have active hepatitis B virus (HBV) or hepatitis C virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded.

    排除标准第 24 条

    Patients who test positive for hepatitis B surface antigen (HBsAg). Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease.

    排除标准第 25 条

    Patients who test positive for HCV antibody. Patients who test positive for HCV antibody will require HCV RNA by quantitative PCR for confirmation of active disease. Patients with a known history of HCV or a positive HCV antibody test will not require an HCV antibody at screening and will only require HCV RNA by quantitative PCR for confirmation of active disease.

    排除标准第 26 条

    Patients who test positive for HIV antibody.

    排除标准第 27 条

  9. Positive serum pregnancy test or women who are breastfeeding.

    排除标准第 1 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07163481,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Female or male patients, 18 years of age or older, able to understand and give written informed consent.
  2. ECOG performance status of 0 or 1.
  3. Men, pre-menopausal or perimenopausal women must use gonadotropin-releasing hormone agonists (such as goserelin) in a standardized manner.
  4. Postmenopausal women must meet one of the following criteria:
  5. bilateral oophorectomy.
  6. age 60 years or older.
  7. age <60 years and natural menopause (not induced by medication) for more than 12 months with follicle-stimulating hormone (FSH) and estradiol levels in the postmenopausal range.
  8. Histologically documented breast cancer that:
  9. Is locally advanced inoperable or metastatic recurrence.
  10. Is documented as HR-positive, HER2-negative (either ER and/or PgR positive [ER or PgR 1%]; HER2 negative [IHC 2+/ISH-; IHC1+/ISH- or untested; IHC 0/ISH- or untested]) per ASCO/CAP guidelines in the metastatic setting. If a patient has had multiple ER/PgR/HER2 results after metastatic disease, the most recent test result will be used to confirm eligibility.
  11. Radiologic or objective evidence of disease progression on or after the last systemic therapy prior to starting study treatment.
  12. Must have had disease progression on CDK4/6i combined with endocrine therapy administrated as the first line and the only therapy for metastatic disease. The time till progression (TTP) for the first line CDK4/6 must be no less than 6 months.
  13. Patients who received adjuvant endocrine therapy with or without CDK4/6i with curative intent for early breast cancer are eligible, as long as they relapse after the first 24 months of adjuvant endocrine therapy.
  14. No prior chemotherapy for advanced or metastatic breast cancer. Patients who have received chemotherapy in the neo-adjuvant or adjuvant setting are eligible, as long as they have had a disease-free interval (defined as completion of systemic chemotherapy to the diagnosis of advanced or metastatic disease) of >12 months.
  15. Measurable disease by CT or MRI in accordance with RECIST v 1.1, the bone-only disease was not measurable and was not permitted.
  16. Adequate hematologic counts without transfusional or growth factor support within 2 weeks of study drug initiation (hemoglobin ≥ 9 g/dL, ANC ≥ 1500/mm 3 , and platelets ≥ 100,000/µL).
  17. Adequate hepatic function (bilirubin ≤ 1.5 × ULN, AST and ALT ≤ 2.5 × ULN or ≤ 5 × ULN if known liver metastases, and serum albumin > 3 g/dL).
  18. Creatinine clearance ≥ 30 mL/min as assessed by the Cockcroft-Gault equation
  19. Recovered from all prior treatment-related toxicities to Grade 1 or less by NCI-CTCAE v 5.0 (except alopecia or peripheral neuropathy, which should be Grade 2 or less).
  20. Willing and able to comply with the requirements and restrictions in this protocol.

排除标准:Exclusion Criteria:

  1. Positive serum pregnancy test or women who are breastfeeding.
  2. Women of childbearing potential or fertile men unwilling to use highly effective contraception during the study and up to 6 months after treatment discontinuation in women of childbearing potential and 3 months in males post last IP administration.
  3. Known hypersensitivity to the study drug, its metabolites, or formulation excipient.
  4. Requirement for ongoing therapy with or prior use of any prohibited medications listed in Section 4.2.6.
  5. Have had a prior anticancer biologic agent within 4 weeks prior to enrollment or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to enrollment and have not recovered (i.e., ≥ Grade 2 is considered not recovered) from AEs at the time of study entry.
  6. Have not recovered (i.e., ≥ Grade 2 is considered not recovered) from AEs due to a previously administered agent.
  7. Note: patients with any grade neuropathy or alopecia are an exception to this criterion and will qualify for the study.
  8. Note: if patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
  9. Have previously received treatment with topoisomerase I inhibitors as a free form or as other formulations.
  10. Have previously received treatment in advanced or metastatic setting with systemic therapy before or after the first line CDK4/6i combined with ET, including but not limited to:
  11. chemotherapy.
  12. endocrine monotherapy or combined with target therapy (PI3Ki, mTORi, AKTi, HDACi, etc.).
  13. PARPi.
  14. immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4, etc.)
  15. antibody-drug conjugates.
  16. Have an active second malignancy. Note: patients with a history of malignancy that have been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or patients with surgically cured tumors with low risk of recurrence (e.g., nonmelanoma skin cancer, histologically confirmed complete excision of carcinoma in situ, or similar) are allowed to enroll.
  17. Met any of the following criteria for cardiac disease:
  18. Myocardial infarction or unstable angina pectoris within 6 months of enrollment.
  19. History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation.
  20. New York Heart Association (NYHA) class III or greater congestive heart failure or left ventricular ejection fraction of < 40%.
  21. Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment.
  22. Have active serious infection requiring antibiotics.
  23. Have known history of HIV-1 or 2 (or positive HIV-1/2 antibody, if done at screening) with detectable viral load OR taking medications that may interfere with SN-38 metabolism.
  24. Have active hepatitis B virus (HBV) or hepatitis C virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded.
  25. Patients who test positive for hepatitis B surface antigen (HBsAg). Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease.
  26. Patients who test positive for HCV antibody. Patients who test positive for HCV antibody will require HCV RNA by quantitative PCR for confirmation of active disease. Patients with a known history of HCV or a positive HCV antibody test will not require an HCV antibody at screening and will only require HCV RNA by quantitative PCR for confirmation of active disease.
  27. Patients who test positive for HIV antibody.
  28. Patients with a history of or current central nervous system (CNS) metastases. A scan to confirm the absence of brain metastases was not required. Patients with unknown CNS metastatic status and any clinical signs indicative of CNS metastases were eligible if CNS metastases were excluded using CT and/or MRI scans.
  29. Patients with Gilberts disease.
  30. Known history of clinically significant active chronic obstructive pulmonary disease, or other moderate-to-severe chronic respiratory illness present within 6 months of the first dose.
  31. High-dose systemic corticosteroids within 2 weeks prior to the first dose (however, low-dose corticosteroids 10 mg prednisone or equivalent daily were permitted if provided the dose was stable for 4 weeks).
  32. Scheduled surgery during the study, other than minor surgery which would not delay study treatment.
  33. Patients who had received a live vaccine within 30 days of the first dose.
  34. Rapid deterioration during Screening prior to the first dose, e.g., significant change in PS, unstable pain symptoms requiring modifications in analgesic management.
  35. Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
  36. Any medical condition that, in the investigators or sponsor's opinion, poses an undue risk to the patient's participation in the study.

引自 ClinicalTrials.gov, NCT07163481, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07163481,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07163481